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1. Introduction 
Two recent studies, the Women’s Health Initiative (WHI) and the Million Women Study 
(MWS), have above all raised concerns over the relationship between progestogens and 
increased risk of breast cancer in the climacteric and postmenopause (Million Women Study 
collaborators, 2003; Writing Group, 2002). The Women’s Health Initiative study was 
terminated early after five years, due to an increased incidence of breast cancer in the group 
treated with combined estrogen and progestogen therapy (EPT). The MWS concluded that 
breast cancer risk was increased two-fold in current users of combined HRT compared to a 
factor of 1.3 for estrogen-only therapy.  
A crucial role of progestogens in increasing breast cancer risk was supported by the WHI 
estrogen mono-arm showing no increase but rather a reduction of breast cancer risk, which 
was significant for patients with more than 80% adherence to study medication (The 
Women’s Health Initiative Steering Committee, 2004). 
However, in the French E3N-EPIC trial of over 80 000 postmenopausal women it was 
reported that hormone therapy containing the progestin medroxyprogesterone acetate or 
norethisterone was associated with a significant increase in risk of breast cancer, whereas 
hormone therapy including progesterone and certain other progestins did not induce an 
increased risk (Fournier et al., 2008). 
By stimulating the production of survival factors, estradiol (E2) and other steroid hormones 
may influence cell proliferation. These survival factors include growth factors and cytokines. 
Epithelial and stromal cell-derived growth factors are understood to be significant in the 
regulation of breast epithelial cells directly via autocrine, paracrine, juxtacrine or intracrine 
pathways. Further responses stimulated by growth factors may activate signalling pathways 
which support the growth of cancer cells (Dickson & Lippman, 1995).  
Progestogens are conventionally thought to act via the activation of the intracellularly-
located progesterone receptors (PR), PR-A and PR-B. Several in vitro studies indicate that 
progestogens may exert an antiproliferative effect by activation of these receptors in human 
breast cancer cells (Cappellatti et al. 1995; Krämer et al., 2006; Schoonen et al., 1995). These 
data are in contrast to the above mentioned clinical data. Other data suggested a 
proliferative effect of synthetic progestogens (Catherino et al., 1995; Franke & Vermes, 2003). 
Thus the mechanisms by which progestogens act on human breast cells remain unclear.  
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Recent experimental data revealed that in addition to the intracellular-located receptors, 
progesterone receptor membrane component-1 (PGRMC1) is associated with a membrane-
associated progesterone receptor activity (Cahill, 2007). PGRMC1 was originally cloned 
from the endoplasmatic reticulum from porcine hepatocytes (Meyer et al., 1996). It contains 
several predicted motifs for protein interactions, and overlapping sites for phosphorylation, 
whose phosphorylation status might correlate with its localisation in the cell (Ahmed et al., 
2010, Cahill, 2007; Munton et al. 2007). PGRMC1 has been detected in several cancers and 
cancer cell lines e.g. breast cancer (Neubauer et al., 2008, 2009). It is overexpressed in lung 
cancer and colon cancer (Cahill, 2007).  
There is a long-standing link between PGRMC1 and progesterone signaling. However, 
because bacterially expressed PGRMC1 does not bind to progesterone (Min et al., 2005), and 
since the majority of PGRMC1 is not localized to the plasma membrane (Crudden et al., 
2005; Nolte et al., 2000; Peluso et al., 2008) it is now tentatively assumed that PGRMC1 does 
not bind P4 by itself (Cahill, 2007), but requires an unknown protein that is associated only 
in partially purified PGRMC1 preparations (Peluso et al., 2008). PGRMC1-associated 
progesterone binding is functionally important in cancer cells because progesterone inhibits 
apoptosis in granulosa cells, and this anti-apoptotic activity requires PGRMC1 (Peluso et al., 
2008a, 2008b). However, it is unclear how PGRMC1 transduces anti-apoptotic signaling by 
progesterone. Expression of PGRMC1 has been identified in several subcellular 
compartments including cell membrane, cytoplasm, endoplasmatic reticulum and nucleus 
(reviewed in Cahill, 2007). Swiatek-De Lange et al. (2007) reported that PGRMC1 localizes to 
the plasma membrane and microsomal fraction of retinal cells.  
In the following our investigations on the effect of progesterone and various synthetic 
progestins on the proliferation of human benign and malignant breast epithelial cells with 
and without expressing PGRMC1 are summarized. 
2. Normal breast epithelial cells 
MCF10A, a human, non-tumorigenic, estrogen and progesterone receptor-negative breast 
epithelial cell line was used for these experiments (Catherino et al., 1995, Soule et la., 1990). 
Progesterone (P4), chlormadinone acetate (CMA), norethisterone (NET), 
medroxyprogesterone acetate (MPA), gestodene (GSD), 3-ketodesogestrel (KDG) and 
dienogest (DNG) were tested at the concentration range of 10-9 to 10-6 M. For stimulation of 
the MCF-10A cells a mixture of growth factors was used. As outcome proliferation and 
apoptosis were measured and the ratio of apoptosis to proliferation was compared. 
Proliferation is quantified by measuring light emitted during the bioluminescence reaction 
of luciferene in the presence of ATP and luciferase. Apoptosis was measured by the Cell 
Death Assay, which is based on the quantitative sandwich-enzyme-immunoassay principle 
using mouse monoclonal antibodies directed against DNA and histones. Photometric 
enzyme immunoassay quantitatively determines cytoplasmic histone-associated DNA 
fragments after induced cell death.  
The combination of the stroma-derived growth factors epithelial growth factor (EGF),basic-
fibroblastic growth factor (FGF) and insulin-like growth factor-I (IGF-I) alone confirmed a 
proliferative response compared to the assay medium-only control. These growth factors 
were chosen, since they have been shown to be most effective in terms of breast epithelial 
cell proliferation (Dickson & Lippman, 1995). 
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In combination with growth factors, the ratio was reduced significantly compared to the 
growth factor alone by MPA and CMA (i.e., favouring an additional proliferative effect). 
MPA produced a four-fold reduction in the ratio in comparison to growth factors alone at 
10-7 M and 10-6 M (p<0.05), CMA had a significant effect at 10-6 M only, reducing the ratio 3-
fold. P4, NET, LNG, DNG, GSD and KDG had no significant effect on the growth factor-
induced stimulation of MCF10A (Table 1).  
 
 Normal cells 
 Growth factors 
Progesterone Ø 
Medroxyprogesterone 
acetate 
-- 
Chlormadinone 
acetate 
-- 
Norethisterone Ø 
Levonorgestrel Ø 
3-Keto-desogestrel Ø 
Gestodene Ø 
Dienogest Ø 
Table 1. Effect of various progestins on the ratio of apoptosis to proliferation in normal 
breast epithelial cells in the presence of stroma-derived growth factors as stimulans. 
(+ = increase; - = decrease of the ratio; Ø = no effect as compared to the stimulans alone) 
3. Cancerous breast epithelial cells 
HCC1500, a human estrogen and progesterone receptor-positive primary breast cancer cell 
line was used (Gazdar et al., 1998). For stimulation of the cells estradiol alone, a growth 
factor mixture alone as well as a combination of both was used.  
The combination of the growth factors EGF, FGF and IGF-I alone confirmed a proliferative 
response compared to the assay medium-only control. MPA in combination with growth 
factors caused a significant increase in the ratio of apoptosis to proliferation at both 
concentrations compared to growth factors alone (p<0.05), the greatest effect being at 10-7 M, 
with a doubling of this ratio, i.e., an inhibitory effect. CMA also caused a significant increase 
in this ratio, with the greatest effect seen at 10-6 M, yielding over a 2-fold ratio increase. 
Conversely, NET, LNG, and DNG at both concentrations and GSD and KDG at 10-6 M led to 
a significant reduction in the ratio of apoptosis to proliferation, enhancing the initial 
proliferative effect induced by the growth factors. P4 had no significant effect at either 
concentration. 
The results of the combination of the steroids and E2 on the estrogen-receptor positive (ER+) 
HCC1500 cells showed that the progestins CMA, MPA, NET, LNG, DNG, GSD and P4 
significantly increased the ratio of apoptosis to proliferation towards an anti-proliferative 
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effect to varying degrees compared to E2 alone, with MPA having the greatest effect, 
followed by NET. KDG had no significant effect at either concentration. No progestin used 
was able to further enhance the stimulatory effect of E2 on HCC1500 cells, and all but KDG 
actually inhibited this effect. 
The results of combining the steroids with the combination of growth factors (EGF, FGF and 
IGF-I) and E2 on HCC1500 cells revealed that MPA, GSD, CMA and NET all increased the 
ratio favouring an anti-proliferative effect compared to the proliferative effect of growth 
factors and E2 alone. P4, LNG, DNG and KDG had no significant effect at either 
concentration. 
 
Progestin Cancerous cells 
 Growth factors Estradiol Growth factors + 
Estradiol 
Progesterone + + + 
Medroxyprogesterone 
acetate 
++ ++ ++ 
Chlormadinone 
acetate 
++ ++ ++ 
Norethisterone -- ++ ++ 
Levonorgestrel -- ++ ++ 
3-Keto-desogestrel -- Ø ++ 
Gestodene - ++ ++ 
Dienogest -- + Ø 
Table 2. Effect of various progestins on the ratio of apoptosis to proliferation in cancerous 
breast epithelial cells in the presence of stroma-derived growth factors, estradiol or a 
combination of both as stimulans. (+ = increase; - = decrease of the ratio; Ø = no effect as 
compared to the stimulans alone) 
In summary these results indicate that progestins are different in their ability to induce 
proliferation or inhibit the growth of benign or malignant human breast epithelial cells 
dependently or independently of the effects of stromal growth factors and E2. Thus on the 
basis of experimental data the choice of progestin for hormone therapy may be important in 
terms of influencing a possible breast cancer risk.  
A further important result from our experimental research seems to be the fact that the 
influence of the progestins can differ largely between normal and cancerous breast epithelial 
cells. This would have clinical relevance for the use of HRT after breast cancer, which is of 
course contraindicated in routine therapy. But as even in the normal population women 
express malignant cells, shown by post mortem analyses (Black & Welch, 1993), different, 
may be contrary progestins effects in benign or malignant cells may have relevance for the 
primary breast cancer risk of postmenopausal women treated with HRT. Therefore this field 
should be further investigated. 
4. Cancerous breast epithelial cells cells overexpressing PGRMC1 
Since the results of the WHI mono arm were published, indicating a negative effect of 
progestins on breast cancer risk, the molecular pathway responsible for this effect and the 
many questions on the extrapolation of the WHI results to all synthetic progestins and to 
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natural progesterone remain unknown. We have published for the first time results 
suggesting that signaling of synthetic progestins via PGRMC1 could be one explanation 
(Neubauer et al., 2009). 
For the experiments two synthetic progestins have been chosen that are widely used in 
hormone therapy, i.e. MPA and NET, as well as a new synthetic progestin, i.e. DRSP, which 
might differ in its behaviour to MPA and NET because of a different chemical structure. In 
addition progesterone and progesterone-3-(O-carboxymethyl) oxime: BSA-fluorescein- 
isothio cyanate conjugate (P4:BSA-FITC) was tested. 
4.1 Transfection of MCF-7 cells 
MCF-7 cells were stably transfected with expression vector pcDNA3.1 containing 
hemeagglutinin-tagged (3HA) PGRMC1 using lipofectamineTM 2000, in accordance with the 
manufacture’s recommendation. A total of 5x105 cells were transfected and plated with 
RPMI-medium for 24h. Then medium was changed to RPMI complete medium containing 
100μg/ml hygromycin B. Cells were cultured for 2 weeks for selection of stable integration 
events. Transfection rates were measured by cotransfection of a GFP expressing plasmid 
and immune fluorescence analysis. After 2 weeks single colonies had formed and limiting 
dilutions were performed three times to select for colonies grown from a single cell.  
Stable transfection was verified by PCR using chromosomal DNA and primers spanning 
intron 1 to distinguish integrated PGRMC1 cDNA from the chromosomal sequence. The 
sequences of the primers were 5’- CTGCTGCATGAGATTTTCACG-3’ hybridizing to 
nucleotides 71 to 91 of PGRMC1 open reading frame and 5’-GCATAGTCCGGGACGTCATA-
3’ hybridizing to the sequence coding for the HA tag. PCR products were sequenced.  
4.2 Effect of synthetic progestins alone 
Dose-dependent effects on cell proliferation of P4, P4:BSA-FITC, MPA, NET or DRSP were 
determined using MTT assay (Fig. 3). Between 10-9M to 10-5M P4 did not increase 
proliferation of either MCF-7 or MCF-7/PGRMC1-3HA cells (WT-12). However, 
proliferation of WT-12 cells was significantly increased when treated with P4:BSA-FITC or 
the synthetic progestogens: for P4:BSA-FITC at concentrations from 10-7 M to 10-5M with a 
maximal effect at 10-6M, for NET reaching its maximal effect compared to untreated control 
at 10-7M, for MPA at concentrations higher than 10-6M, and for DRSP at concentrations 
higher than 10-7M. The effect of NET was significantly different to that one of DRSP at the 
concentrations of 10-9 and 10-8 M and to the effect of MPA at the concentrations of 10-9, 10-8 
and 10-7 M. DRPS showed a significant stronger effect as compared to MPA at the 
concentration of 10-7 M. No effects were observed in MCF-7 cells within the investigated 
concentration ranges for all the progestogens used in this experiment. 
For further kinetic experiments 10-6M was chosen for all progestogens. In comparison to all 
other synthetic progestins tested NET significantly increased proliferation almost to maximum 
even at 10-9M, the lowest concentration that we tested. Taken together, the results strongly 
suggested that some synthetic progestins elicit a PGRMC1-dependent proliferative response. 
To determine time-dependent proliferative effects of progestogens a kinetic analysis over 6 
days was performed (Fig. 4). MCF-7 and WT-12 cells were incubated with P4, P4-BSA-FITC, 
DRSP, MPA and NET at 10-6M and proliferation was determined by MTT assay. The results 
indicate that P4:BSA-FITC, DRSP, MPA and NET increased proliferation in WT-12 cells by 
approximately 3.5 to 4 fold on day 6 which is highly significant compared to the 
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simultaneously cultured untreated control cells. No effects on proliferation were observed 
for P4, DRSP, MPA and NET in MCF-7 cells. Only the membrane-impermeable P4-BSA-
FITC caused a marginal increase of proliferation in the parental MCF-7 cells by 
approximately 1.5 fold compared to the control cells.  
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Fig. 3. Titration of progesterone and synthetic progestins. MCF-7 and MCF-7/PGRMC1-
3HA (WT-12) cells were incubated with either progesterone (P4), P4:BSA-FITC, DRSP, MPA, 
and NET from 10-5M to 10-9M in tenfold dilution steps. Cell proliferation was measured after 
4 days. Data were normalized to unstimulated controls. (means ± SD; ** p< 0.01 vs. controls) 
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Fig. 4. Kinetic analysis of proliferation. MCF-7 and MCF-7/PGRMC1-3HA (WT-12) cells 
were incubated with either progesterone (P4), P4:BSA-FITC, DRSP, MPA, and NET at 10-6M. 
Cell proliferation was measured daily for 6 days (D1–D6). Data were normalized to 
unstimulated controls. (means ± SD; * p< 0.05; ** p< 0.01 vs. controls) 
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4.3 Combination of progestogens with estradiol in PGRMC1 overexpressing cells  
In our further investigations we showed that estradiol in a dosage that increased cell 
numbers of MCF-7 cells was able to induce an effect in WT-12 cells that doubed the effect in 
MCF-7 cells (Neubauer et al, 2010). The concentration of 10-10 M was chosen, because it is 
equally to in vivo serum concentrations achieved with transdermal or low orally estradiol 
application. The concentration of 10-12 M was chosen in order to imitate very low serum 
estradiol concentrations that were not able to induce a measurable breast cancer risk. The E2 
effect could be blocked by the addition of the potent estrogen receptor antagonist fulvestrant 
indicating that the intracellular estrogen receptor-alpha is involved. However, since the 
proliferation was twice as high as in MCF-7 cells, in the presence of PGRMC1 a mechanistic 
interaction between the estrogen receptor-alpha and PGRMC1 signaling systems seems to 
be highly possible. The mechanism(s) of interaction is currently unknown. Of special 
significance are our findings in terms of adding progesterone or medroxyprogesterone 
acetate to estradiol. When PGRMC1 is overexpressed the E2-induced effect is more 
pronounced, but P4 still displayed a neutral effect. However, the addition of MPA triggered 
a strong proliferative signal in the presence of this E2 concentration (Fig. 5). The effect of 
other synthetic progestogens in combination with E2 on the proliferation of MCF-7 cells 
overexpressing PGRMC1 is currently under investigation. 
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Fig. 5. MCF-7/PGRMC1-3HA (WT-12) cells were incubated with estradiol (E2, 10-10 M or 10-
12 M) alone and in combination with either progesterone (P, 10-6 M) or medroxyprogesterone 
acetate (MPA, 10-6 M). Cell proliferation was measured after 4, 5 and 6 days. Data were 
normalized to unstimulated controls. (Means ±SD; ** p< 0.01 vs. E2) 
5. Discussion 
The proliferation of normal and malignant cells is under the control of both estrogen and 
growth factors. In normal epithelial cells, estrogen-receptor expressing cells represent only a 
minority of the total cells and do not proliferate (Ali & Coombes, 2002). Current opinion is 
that estrogens act proliferatively in a paracrine fashion by inducing the production of 
stromal-derived growth factors and cytokines or their receptors via the activation of 
epithelial or stromal estrogen receptors. Growth factors may play an important role in the 
promotion of receptor-positive breast cancer by cross-talk with the steroid-receptor and are 
mainly responsible for the progression of estrogen-receptor negative breast cancer. Among 
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the growth factors which are important for cell growth are the epidermal growth factor 
(EGF) family, insulin-like growth factors I and II (IGF-I and IGF-II), fibroblast growth factors 
(FGFs), transforming growth factor- (TGF-) and platelet-derived growth factors (PDGFs).  
It is important to differentiate between normal and malignant estrogen-receptor positive 
breast cells. Therefore, for the first time, we have investigated the effect of eight different 
progestogens on the proliferation of benign and malignant breast epithelial cells in the 
presence of growth factors and/or estradiol. 
Our results indicate that MPA may enhance the mitotic rate of normal epithelial breast cells 
in the presence of growth factors and thus may increase the probability of faults in DNA-
replication when used in long-term. Indeed, the results of WHI indicate that patients who 
were not using hormones prior to the start of the study had no increased hazard ratio for 
breast cancer whereas subjects with prior hormone use for up to five, five to ten and more 
than 10 years showed an increasing risk (Writing Group, 2002). These data suggest that 
long-term use of MPA may increase breast cancer risk by enhancing the mitotic rate of 
normal epithelial cells.  
We could further demonstrate that progesterone had a neutral effect on growth-factor 
stimulated healthy breast epithelial cells. In the case of cancerous breast cells, other groups 
have published supporting results, where E2-induced stimulation of MCF-7 cells has been 
shown to be inhibited by progesterone (Cappellatti et al., 1995; Mueck et al., 2004; Schoonen 
et al., 1995; Seeger et al., 2003). Up to now, there is a paucity of data available regarding the 
effects of CMA and LNG on the proliferation of normal and malignant epithelial breast cells. 
There are also conflicting epidemiological data concerning these progestogens (Ebeling et 
al., 1991; Nischan et al., 1984; Persson et al., 1996). DNG has been shown to elicit potent anti-
tumour activity against hormone-dependent cancer types in an animal model and has 
exhibited slight concentration-dependent inhibitory effects in combination with E2, in 
agreement with our results (Katsuki et al., 1997). GSD and KDG have been shown to be able 
to inhibit cell proliferation of a specific sub-clone of MCF-7 in the presence of E2 (Schoonen 
et al., 1995). Our results support the inhibitory effects of both GSD and KDG in combination 
with E2, however, we found both exhibited a proliferative effect on HCC1500 cells with 
growth factors alone.  
By comparing the cell death to proliferation ratio results of growth factors alone, E2 alone 
and combination of growth factor and E2 on HCC1500 cells, we also found that the single 
proliferative effects of growth factors or E2 alone are magnified when in combination with 
each other, which, however, was not always statistically significant. The mechanism of the 
stimulatory effect of MPA (and of CMA) on MCF10A cells is currently unknown, as this cell 
line is both estrogen and progesterone receptor negative. The effects of the steroids on 
HCC1500 cells appear to be receptor-dependent, since the time course clearly shows a long-
term effect rather than a rapid non-genomic action.  
For the first time we could present data suggesting that signaling of synthetic progestins via 
PGRMC1 could be one explanation for the clinically observed possible induction of breast 
cancer risk by progestins. We have chosen two synthetic progestins that are widely used in 
hormone therapy, i.e. MPA and NET, as well as a new synthetic progestin, i.e. DRSP, which 
might differ in its behaviour to MPA and NET, because of a different chemical structure.  
The synthetic progestins MPA, NET and DRSP significantly induced a relatively large 
proliferative effect in MCF-7 cells that overexpress PGRMC1. For P4, however, no such 
effect was found. Since progesterone and the synthetic progestins used in HT are able to 
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activate PR-A/-B and PGRMC1 simultaneously, our data suggest that in vivo the balance of 
the expression levels of both receptors might influence whether epithelial cells proliferate or 
not in the presence of progestogens. Therefore, it may be instructive to determine the 
expression ratio of PGRMC1 and PR-A/-B before HT. 
Interestingly, P4:BSA-FITC is able to induce a marginal proliferative signal in MCF-7 cells 
(Fig. 3). P4:BSA-FITC is thought to be unable to cross the plasma membrane and can 
therefore only bind to membrane associated progesterone receptors. MCF-7 cells express 
endogenous PGRMC1 at very low amounts (data not shown), which may transduce the 
weak proliferative signal since the classical PR-A/-B response is not triggered. The synthetic 
progestins and P4 bind to all progesterone receptors expressed by MCF-7 cells. Binding to 
PR-A/-B might transduce an antiproliferative signal, countermanding the proliferative 
signal induced by low levels of PGRMC1. In contrast, in WT-12 cells the exogenously 
expressed PGRMC1 might overrule the antiproliferative effect of PR-A/-B. In several 
human ovarian surface epithelial cell lines, P4 inhibits their proliferation (Syed et al., 2001). 
Because these cells express the PR-A/-B it has been assumed that P4’s actions are mediated 
via these receptors. However, P4 exhibits antimitotic action only at micromolar doses, which 
have been used in these experiments (Syed et al., 2001). Given that the dissociation constant 
for the PR-A/-B is 1–5 nm (Stouffer, 2003) and for PGRMC1 is in the 0.20–0.3 µm range 
(Meyer et al., 1996), which is well within the levels of P4 in serum and in follicular fluid 
(Stouffer, 2003), in MCF-7 cells the classical PR-A/-B receptors are perhaps activated 
preferentially by gestagens inducing an anti proliferative signal. This concept is supported 
by a previous observation that at micromolar doses P4 inhibits granulosa cell and 
spontaneously immortalized granulosa cell (SIGC) mitosis (Fujii et al., 1983).  
Interestingly, NET exerts its activity on proliferation already at the lowest concentration 
tested (10-9 M, Fig. 4) whereas DRSP and MPA increase proliferation only at higher 
concentrations (10-7 M and 10-6 M). This suggests that NET binds PGRMC1 with the highest 
affinity, followed by DRSP and MPA. Compared to PR-A/-B this is different since the latter 
binds MPA better than NET (Kuhl, 1998). These results indicate that HT including NET 
might result in an increased risk for breast cancer development. Indeed, some studies in 
which norethisterone- or levonorgestrel-derived progestogens were continuously 
administered a significantly higher risk for breast cancer was observed than for 
continuously administered progesterone-derived progestogens (Lyytinen et al., 2009; 
Magnusson et al., 1999). In one study the use of norethisterone acetate was accompanied 
with a higher risk after 5 years of use (2.03, 1.88-2.18) than that of medroxyprogesterone 
acetate (1.64, 1.49-1.79) (Lyytinen et al., 2009). It is known that NET can be converted in vivo 
into ethinylestradiol (Kuhnz et al., 1997). In as far this conversion may influence the 
observed NET effect is currently unknown and is under investigation.  
Despite their widespread use, in vitro models have certain limitations: the choice of culture 
conditions can unintentionally affect the experimental outcome, and cultured cells are 
adapted to grow in vitro; the changes which have allowed this ability may not occur in vivo. 
Limitations of this in vitro study might be the high concentrations needed for an effective 
antiproliferative effect. The clinically relevant blood concentrations for the progestogens 
most commonly used for HRT, MPA and NET, are in the range of 4x10-9M to 10-8M for MPA 
(Svensson et al., 1994) and around 10-8M for NET (Stanczyk et al., 1978). However, higher 
concentrations may be required in vitro in short-time tests in which the reaction threshold 
can only be achieved with supraphysiological dosages. Higher concentrations may also be 
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reached in vivo in the vessel wall or organs compared to the concentrations usually 
measured in the blood.  
A further limitation of our work is the short incubation period of the cells with the 
substrates under investigation, in comparison to the longer time period for which hormone 
therapy is usually prescribed. That duration of therapy may indeed be an important factor 
for breast cancer risk is emphasized by the results of WHI, where breast cancer risk was 
significantly higher compared to placebo only in women given combined HRT for 10 years 
or more, but not in those treated only for the duration of the study period, i.e. 5.2 years 
(Writing Group, 2002). In vitro experiments can support, but not replace clinical trials, and 
therefore, further clinical studies are needed to determine which progestogens, if any, have 
the lowest breast cancer risk.  
6. Conclusion 
Experimental data with the comparison of various synthetic progestins in the same in vitro 
model present rather high evidence that there may be differences between the various 
progestins regarding breast cancer risk. Especially of concern may be to differentiate 
between primary and secondary risk i.e. between benign and malignant breast epithelial 
cells. This differentiation seems to be especially important for the progestin MPA. Since 
even in ‘clinically healthy’ women malignant cells can be detected (Nielsen et al., 1987), this 
experimental finding may have relevance and should be further investigated.  
The effect of progestins on breast cancer tumorigenesis may depend on the specific 
progestin used for hormone therapy and the expression of PGRMC1, PR-A and PR-B in the 
target tissue. However, in terms of the clinical situation it remains unknown how uniformly 
PGRMC1 is expressed in the normal breast epithelial cells between patients. Thus screening, 
which might be based on determining the expression ratio of PGRMC1 and PR in cells from 
nipple aspirate fluid (NAF), might be of interest to identify women who show an increased 
expression of PGRMC1 and who might thus be susceptible for breast cancer development 
under HT (Sauter et al., 1997). The data presented here are of dramatic importance in terms 
of progesterone and breast cancer risk in HT clinical studies so far (Writing Group for the 
Women’s Health Initiative Investigators, 2002; The Women’s Health Initiative Steering 
Committee, 2004). The epidemiological studies and especially the WHI trial, so far the only 
prospective placebo-controlled interventional study, demonstrate an increased risk under 
combined estrogen/progestin therapy, but they have the limitations that they up to now can 
not discriminate between the various progestins mostly due to too small or not comparable 
patient numbers in the subgroups with the various progestins. However, there is evidence 
that the natural progesterone, possibly also the transdermal usage of synthetic progestins, 
may avoid an increased risk, but this must be proven in further clinical trials. 
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